Equity Overview
Price & Market Data
Price: $3.70
Daily Change: -$0.15 / 4.05%
Range: $3.49 - $3.85
Market Cap: $2,724,794
Volume: 10,612
Performance Metrics
1 Week: 8.81%
1 Month: 6.66%
3 Months: -17.51%
6 Months: -60.77%
1 Year: -75.75%
YTD: -14.96%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.